Results 221 to 230 of about 31,219 (282)

The nonsteroidal MR antagonist finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation. [PDF]

Am J Physiol Renal Physiol
Myakala K, Wang XX, Shults N, Hughes EP, de Carvalho Ribeiro P, Penjweini R, Link K, Barton K, Krawczyk E, Clarkson Paredes C, Popratiloff A, Knutson JR, Cowart AL, Levi M.   +13 more
europepmc   +1 more source

Inhibitory Effects of Bisphenol Z on 11β-Hydroxysteroid Dehydrogenase 1 and In Silico Molecular Docking Analysis. [PDF]

Molecules
Tuzimski T, Sugajski M.
europepmc   +1 more source

Deficiency of mineralocorticoid receptor signalling in myeloid cells protects cardiac and kidney function in hypertensive diabetic mice. [PDF]

Clin Sci (Lond)
Tesch GH, Ozols E, Morgan J, Young MJ, Nikolic-Paterson DJ.   +4 more
europepmc   +1 more source

Protocol for the FibroCAN study: a randomised controlled trial of finerenone treatment for early-stage cardiovascular autonomic neuropathy in type 2 diabetes. [PDF]

BMJ Open
Bitsch Poulsen M, Okdahl T, Buciek JH, Drewes AM, Karlsson P, Ahluwalia TS, Brock B, Brock C, Rossing P, Hansen CS.   +9 more
europepmc   +1 more source

Aldosterone and Diabetes Risk: An Association in Need of Mechanistic Insights.

J Clin Endocrinol Metab
Echouffo-Tcheugui JB, Dagogo-Jack S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

Current Hypertension Reports, 2020
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta, Eiichiro, Yamamoto, Kenichi, Tsujita   +2 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists

Current Hypertension Reports, 2007
With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of
Parthasarathy, Hari Krishnan, MacDonald, Thomas M.   +1 more
openaire   +3 more sources